Last reviewed · How we verify
HERCESSI (TRASTUZUMAB-STRF)
HERCESSI (generic name: TRASTUZUMAB-STRF) is a drug developed by ACCORD BIOPHARMA INC.. It is currently FDA-approved.
Herceptin (ABP-980) is an antibody that inhibits the receptor protein-tyrosine kinase erbB-2, and it is being studied in clinical trials for various breast cancer conditions, including anatomic stages I, II, and IV, as well as metastatic and oligometastatic breast carcinoma.
At a glance
| Generic name | TRASTUZUMAB-STRF |
|---|---|
| Sponsor | ACCORD BIOPHARMA INC. |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Neutropenia
- Fever
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Anemia
- Infusion reactions
- Infections
- Increased cough
- Headache
- Dyspnea
Serious adverse events
- Cardiac failure
- Hypersensitivity
- Asymptomatic cardiac dysfunction
- Interstitial pneumonitis
- Pulmonary hypertension
- Ventricular disorder
- Autoimmune thyroiditis
- Cardiac disorder
- Febrile neutropenia
- Sudden death
Key clinical trials
- A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy (Phase 3)
- A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Pacl (Phase 3)
- MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients With Non-Breast, Non-Gastric/GEJ, and Non-Colorectal Cancers With HER2 Amplification (Phase 2)
- HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Loc (Phase 1)
- A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers (Phase 2)
- Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer (Phase 3)
- Molecular Analysis for Therapy Choice (MATCH) (Phase 2)
- A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HERCESSI CI brief — competitive landscape report
- HERCESSI updates RSS · CI watch RSS
- ACCORD BIOPHARMA INC. portfolio CI
Frequently asked questions about HERCESSI
What is HERCESSI?
Who makes HERCESSI?
What is the generic name of HERCESSI?
What development phase is HERCESSI in?
What are the side effects of HERCESSI?
Related
- Manufacturer: ACCORD BIOPHARMA INC. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing